Characterization of two melanoma cell lines resistant to BRAF/MEK inhibitors (vemurafenib and cobimetinib)
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Characterization of two melanoma cell lines resistant to BRAF/MEK inhibitors (vemurafenib and cobimetinib) ; volume:22 ; number:1 ; day:23 ; month:8 ; year:2024 ; pages:1-21 ; date:12.2024
Cell communication and signaling ; 22, Heft 1 (23.8.2024), 1-21, 12.2024
- Urheber
-
Kot, Magdalena
Simiczyjew, Aleksandra
Wądzyńska, Justyna
Ziętek, Marcin
Matkowski, Rafał
Nowak, Dorota
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12964-024-01788-3
- URN
-
urn:nbn:de:101:1-2411120854116.075311048432
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kot, Magdalena
- Simiczyjew, Aleksandra
- Wądzyńska, Justyna
- Ziętek, Marcin
- Matkowski, Rafał
- Nowak, Dorota
- SpringerLink (Online service)
Ähnliche Objekte (12)
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
MEK + CDK4 a regimen for non-BRAF V6000 melanoma
Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines
Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells
RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors
Gene Expression Signature of BRAF Inhibitor Resistant Melanoma Spheroids
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes
Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma
Targeting EphA2 and DDR signaling can overcome the BRAF and MEK inhibitors acquired resistance in melanoma cell lines
RICTOR/mTORC2 downregulation in BRAFV600E melanoma cells promotes resistance to BRAF/MEK inhibition
Triplet Therapy in Melanoma — Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
MEK + CDK4 a regimen for non-BRAF V6000 melanoma
Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines
Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells
RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors
Gene Expression Signature of BRAF Inhibitor Resistant Melanoma Spheroids
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes
Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma
Targeting EphA2 and DDR signaling can overcome the BRAF and MEK inhibitors acquired resistance in melanoma cell lines
RICTOR/mTORC2 downregulation in BRAFV600E melanoma cells promotes resistance to BRAF/MEK inhibition
Triplet Therapy in Melanoma — Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
MEK + CDK4 a regimen for non-BRAF V6000 melanoma
Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines
Influence of BRAF-/MEK-inhibitors on the immunogenicity of melanoma cells
RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors
Gene Expression Signature of BRAF Inhibitor Resistant Melanoma Spheroids
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes
Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma
Targeting EphA2 and DDR signaling can overcome the BRAF and MEK inhibitors acquired resistance in melanoma cell lines
RICTOR/mTORC2 downregulation in BRAFV600E melanoma cells promotes resistance to BRAF/MEK inhibition